GIGABYTE-TECHNOLOGY
4.6.2021 11:38:50 CEST | Business Wire | Press release
GIGABYTE Technology, a leading brand of computer innovations, continues its strong presence at COMPUTEX, joining the “#COMPUTEXVirtual” platform as the exhibition takes place online due to global pandemic situation. From May 31st to June 30th , GIGABYTE orchestrated 10 different sections in a dedicated “GIGABYTE Pavilion” to exhibit a series of products and solutions that can expand on its “Bring Smart to Life” concept, from the data center to personal computer, and 5G to edge AI computing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210604005208/en/
GIGABYTE is known for having the most extensive portfolio of AMD servers for demanding workloads, and has readied a comprehensive lineup of servers supporting the 7nm processor, unlocking its incredible performance of up to 64 cores and 128 threads to enable developers and scientists to tackle challenges in HPC and cloud computing. Correspondingly, GIGABYTE is primed to present Intel servers based on the latest 3rd Gen. Intel® Xeon® Scalable Processors suited for enterprises looking to upgrade their IT infrastructure.
At the forefront of server development is an NVIDIA Arm HPC Developer Kit, a system that includes an Ampere Altra processor, two NVIDIA A100 Tensor Core GPUs, and two NVIDIA BlueField®-2 DPUs, all contained in a leading-edge GIGABYTE G242 server. In addition, GIGABYTE will present four ARM server products, all of which can leverage the power of the 80-core (250W) Ampere Altra processors to provide outstanding efficiency, performance, and throughput.
Smart cities benefited from the computing power of data centers through GIGABYTE’s industrial motherboards, embedded systems, automotive electronics, 3D depth sensing solutions, visual recognition solutions, and deep learning-based AI training and inferencing programs. Notable exhibits will include Industry 4.0 factory automation and smart retail solutions, in-vehicle ECU and AI edge computing platforms, and AI facial recognition systems.
PC consumers are treated with AORUS and AERO premium laptops, now powered by Intel’s latest 11th Gen Tiger Lake-H series processors, while pairing with the full-power RTX 30 series graphics cards and 4K OLED panels respectively; new AORUS 4K gaming monitors equipped with exclusive tactical game-enhancement features and HDMI 2.1-ready for full support of the new-gen gaming consoles; and two prebuilt AORUS flagship systems that are the world’s first factory-tuned gaming desktops, with the most powerful component to date, and tuned and tested to ensure impeccable stability and performance out of the box.
Visit “GIGABYTE Pavilion”
https://virtual.computextaipei.com.tw/area/gigabyte/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005208/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom